Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial

Alan Winston, Martin S. Rhee(Gilead Sciences (United States)), Patrick Mallon(University College Dublin), Mingjin Yan(Seagen (United States)), Paula Peyrani(University of Louisville), Francesco Castelli(University of Brescia), Frank A. Post(King's College Hospital NHS Foundation Trust), Moupali Das(University of California, San Francisco), Stephanie Cox, Peter Ruane, Gordon Crofoot(Clinical Research Organization), Edwin DeJesus(Orlando Immunology Center), Daniel Podzamczer(Bellvitge University Hospital), Giovanni Di Perri(University of Turin), Andrew Cheng(Gilead Sciences (United States)), François Raffi, Vicente Estrada(Instituto de Salud Carlos III)
The Lancet HIV
February 21, 2018
10.1016/s2352-3018(18)30010-9
Cited by 27

Related Papers

On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection
|New England Journal of Medicine|2015|1.6k
Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy
|JAMA|2016|1.4k
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study
|The Lancet|2019|1k
Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV
|New England Journal of Medicine|2006|886
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
|JAMA|2021|728